| 言語 |
英語
|
| 著者 |
Sato Shuichi
Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Izumo, Japan
Miyake Tatsuya
Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Izumo, Japan
石原 俊治
医学部内科学講座内科学第二
|
| 主題 | nonalcoholic; steatohepatitis; type 2 diabetes mellitus; sodium-glucose; cotransporter 2-inhibitor; dapagliflozin; open-label
|
| 掲載誌名 |
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
|
| 巻 | 87
|
| 開始ページ | 13
|
| 終了ページ | 19
|
| ISSN | 0011-393X
|
| ISSN（Online） | 1879-0313
|
| 発行日 | 2017
|
| DOI | |
| PubMed ID | |
| 出版者 | ELSEVIER SCIENCE INC
|
| 資料タイプ |
学術雑誌論文
|
| 部局 |
医学部
|
| 備考 | Dapagliflozin was developed by AstraZeneca, who provided funding for publication fees and development of the manuscript, but did not play any other role in the study design; collection, analysis, and interpretation of data; writing of the manuscript; or the decision to submit the manuscript for publication. HT and YK have received honoraria from AstraZeneca K.K. Funding to pay for editorial support and the Open Access publication charges for this article were provided by AstraZeneca K.K. and Ono Pharmaceutical Co, Ltd. The authors have indicated that they have no other conflicts of interest regarding the content of this article.
|
